Washington University School of Law,
J.D., cum laude
Thompson Coburn LLP
Al Masaken International Real Estate Development Co.
Chief Executive Officer, 2011–2018
Chief Operating Officer, 2010–2018
Nabil assists clients in a broad range of corporate and securities areas, including mergers, acquisitions, and capital markets.
Nabil's transactional practice focuses on corporate and securities matters. Nabil supports clients in achieving their unique goals, with a special emphasis on mergers and acquisitions structures, including stock acquisitions, asset acquisitions, and reverse mergers. Nabil has experience in all stages of the M&A process, including structure considerations, financing requirements, purchase agreements, ancillary documents, and closing coordination. He is naturally meticulous, thoughtful, and exacting, and enjoys using those attributes in all aspects of his practice.
Nabil leverages his corporate law background with his prior decade-long experience serving as executive and board member of several international publicly owned companies. In the corporate space, he assists clients with corporate formations, entity conversions, and state law considerations. In the capital markets sphere, Nabil grasps an intimate knowledge of the federal securities laws and many Securities and Exchange Commission (SEC) regulations, based on which he assists public companies with the preparation and filing of annual reports, 10-K filings, 8-K filings, among other securities, disclosures and SEC compliance requirements.
Nabil graduated cum laude from Washington University School of Law, prior to which he earned an MBA from Columbia University. In law school, he served as Senior Executive Editor at the Washington University Law Review, and received the Mary Collier Hitchcock Prize and the Judge Myron D. Mills Administrative Law Award for outstanding legal writing in recognition of his published writing. He also served as an extern for Judge R. Stephen Clark of the United States District Court for the Eastern District of Missouri.
SEC adopts new executive clawback requirements for erroneously awarded compensation
Navigating the Maze of Psychedelics Therapeutics: Tracking the Trends in State and Federal Reschedulings
American Bar Association - Health eSource June 2022
MDMA and Psilocybin for Mental Health: Deconstructing the Controlled Substances Act’s Usage of “Currently Accepted Medical Use”
Washington University Law Review March 2022
Although we would like to hear from you, we cannot represent you until we know that doing so will not create a conflict of interest. Also, we cannot treat unsolicited information as confidential. Accordingly, please do not send us any information about any matter that may involve you until you receive a written statement from us that we represent you (an ‘engagement letter’).
By clicking the ‘ACCEPT’ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the ‘ACCEPT’ button if you understand and accept the foregoing statement and wish to proceed.